Related Experiment Video

Updated: Jun 11, 2026

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

NF1 inactivation revs up Ras in adult acute myelogenous leukemia

Ann Mullally1, Benjamin L Ebert

  • 1Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|July 1, 2010
PubMed

Insights

Neurofibromatosis type 1 (NF1) inactivation in acute myelogenous leukemia (AML) sensitizes cancer cells to mTOR inhibition. This finding reveals a potential therapeutic strategy for AML patients with NF1 mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ras pathway mutations are frequent in myeloid malignancies.
  • Neurofibromatosis type 1 (NF1) acts as a tumor suppressor and negatively regulates the Ras pathway.
  • NF1 inactivation occurs in a subset of adult acute myelogenous leukemia (AML) cases.

Purpose of the Study:

  • To investigate the functional consequences of NF1 inactivation in AML.
  • To explore the therapeutic potential of targeting downstream effectors of Ras activation in NF1-deficient AML.

Main Methods:

  • Analysis of Ras pathway signaling in AML cells with and without NF1.
  • Assessment of cellular sensitivity to mammalian target of rapamycin (mTOR) inhibitors in NF1-mutated AML models.

Main Results:

  • Loss of NF1 function leads to Ras pathway activation.
  • NF1-deficient AML cells exhibit increased sensitivity to mTOR inhibition.
  • Targeting mTOR represents a viable therapeutic strategy for this AML subset.

Conclusions:

  • NF1 inactivation is a key event in a subset of AML, driving Ras pathway activation.
  • Inhibition of mTOR is a promising therapeutic avenue for AML patients with NF1 mutations.
  • Understanding Ras pathway dysregulation in AML offers opportunities for targeted therapies.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...